IMNM

Rating neutralTentativeAI MemoPost-earnings T+1

Immunome

As of 2026-08-20/Post-earnings T+1/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-20 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

memo remains a monitoring view with limited forward evidence and should not be standard-conviction

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Varegacestat FDA review and PDUFA decision • 2027-04-28

Base target: $34 / p=50% prob

Biggest risk

The thesis remains dependent on regulatory approval, early-stage clinical execution and eventual commercialization. The available packet does not establish a verifiable Q2 consensus revenue or EPS surprise, and continued R&D spending could bring financing risk forward if development costs rise. Recent director and officer open-market sales add a modest supply and sentiment risk. [#SEC-FORM4-2026-08-12] [#SEC-FORM4-2026-08-10]

Invalidation

Break below $19 or thesis failure.

What would change my mind?

The post-earnings update strengthens the milestone stack: positive Phase 3 RINGSIDE results, FDA acceptance of the varegacestat NDA, a defined April 2027 PDUFA date, multiple newly enrolling programs and runway into 2028. A reported Wedbush update raised its price target from $31 to $35 while maintaining Outperform. [Yahoo Finance](https://finance.yahoo.com/markets/stocks/articles/wedbush-adjusts-price-target-immunome-111009182.html)

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-20

Base target

$34

p=50%

Bull target

$48

p=25%

Bear target

$19

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Cash runway limits near-term financing pressure
IM-1021 initial lymphoma data
Broader pipeline advances through early clinical development

BearKey bullets

IM-1021, IM-1617 and IM-3050 are early-stage programs with safety, enrollment, efficacy and execution risk.
R&D spending and pipeline expansion could reduce the stated cash runway or create future dilution pressure.
Recent open-market sales by a director and the Chief Business Officer may weigh on sentiment, although they do not directly indicate operating deterioration.

WatchKey bullets

Varegacestat FDA review and PDUFA decision

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $34 (p=50%)

Target spread vs base: +41% / -44%

Scenario probabilities

Bull Target: $48 (p=25%)Base Target: $34 (p=50%)Bear Target: $19 (p=25%)

Commentary

The T+1 earnings follow-up modestly improves the event profile through FDA acceptance, a defined PDUFA date, positive RINGSIDE data and multiple pipeline starts. Analyst revision evidence is limited to a reported Wedbush target increase, while broader consensus reaction and post-print attribution are unavailable. This remains a cautious monitoring setup with asymmetric milestone optionality rather than a clean fundamental long.

As of 2026-08-20 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Cash runway limits near-term financing pressure
IM-1021 initial lymphoma data
Broader pipeline advances through early clinical development

Scenarios

Bull Target (Scenario probability)

$48 / p=25% prob

Base Target (Scenario probability)

$34 / p=50% prob

Bear Target (Scenario probability)

$19 / p=25% prob

Analysis 2026-08-20 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2027-04-28
Varegacestat FDA review and PDUFA decision
The FDA accepted Immunome’s NDA for varegacestat and assigned an April 28, 2027 PDUFA target action date. Strong RINGSIDE Phase 3 results provide clinical support, but approval and commercial execution remain unproven. [#SEC-8K-2026-08-11]
Prob 85.00% • Move 18.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

Cash runway limits near-term financing pressure
2026-12-31
Q2 materials reported $520.0 million in cash, cash equivalents and marketable securities as of June 30, 2026, with funding expected into 2028. This supports continued development but does not eliminate future dilution risk. [#SEC-8K-2026-08-11] [#PR-EARNINGS-2026-08-11]
Prob 85% • Move 5% • Priced-in 70%

Long-term Catalysts

Months to a year

IM-1021 initial lymphoma data
2026-12-31
The Phase 1 IM-1021 study is ongoing, with objective responses observed at multiple dose levels; initial lymphoma data are expected in 2026. Early oncology data remain highly volatile. [#SEC-8K-2026-08-11]
Prob 60% • Move 22% • Priced-in 35%
Broader pipeline advances through early clinical development
2026-12-31
IM-1617 and IM-3050 have dosed their first patients, while three additional clinical-stage programs are enrolling. Planned IND submissions for IM-1340 and IM-1335 could add further pipeline optionality in 2026. [#SEC-8K-2026-08-11]
Prob 70% • Move 12% • Priced-in 30%

Risks

IM-1021, IM-1617 and IM-3050 are early-stage programs with safety, enrollment, efficacy and execution risk.
R&D spending and pipeline expansion could reduce the stated cash runway or create future dilution pressure.
Recent open-market sales by a director and the Chief Business Officer may weigh on sentiment, although they do not directly indicate operating deterioration. [#SEC-FORM4-2026-08-12] [#SEC-FORM4-2026-08-10]
Varegacestat approval, labeling and launch remain uncertain despite positive Phase 3 data and FDA acceptance.

Peers

Symbol	Summary
IOVA	Iovance is a closer oncology development-stage comparator than large-cap peers, but its cell-therapy model differs materially. It is useful mainly for milestone, manufacturing and clinical-execution risk benchmarking.
IRON	Disc Medicine is a similarly sized development-stage biopharma with milestone-driven valuation, though its hematology focus is not directly comparable to Immunome’s oncology pipeline.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-20

Loading AI feed…

Symbol

Summary

IOVA

Iovance is a closer oncology development-stage comparator than large-cap peers, but its cell-therapy model differs materially. It is useful mainly for milestone, manufacturing and clinical-execution risk benchmarking.

IRON

Disc Medicine is a similarly sized development-stage biopharma with milestone-driven valuation, though its hematology focus is not directly comparable to Immunome’s oncology pipeline.